On 24 March 2020, orphan designation EU/3/20/2264 was granted by the European Commission to Premier Research Group S.L., Spain, for trifarotene (also known as CD5789) for the treatment of autosomal recessive congenital ichthyosis.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in June 2022 on request of the Sponsor.
Treatment of autosomal recessive congenital ichthyosis
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: